Pretreatment with Pentoxifylline and<i>N</i>-Acetylcysteine in Liver Ischemia Reperfusion-Induced Renal Injury

Seifi, Behjat; Kadkhodaee, Mehri; Delavari, Farnaz; Mikaeili, Saideh; Shams, Salman; Ostad, Seyed Nasser

doi:10.3109/0886022x.2012.660827

Cited by 31 publications

(26 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…GSH, a scavenger of free radicals, was found to be depleted in animals administered with carboplatin indicating the role of ROS and diminishing antioxidant defenses in nephrotoxic conditions. PTX mediated improvements in renal GSH levels were only marginal in the carboplatin-intoxicated group since the change in GSH levels is very small and this is contrary to previous reports (Seifi et al, 2012) involving PTX in renal conditions. However, it was presumed that this might be due the extremely short protocol used for PTX treatment.…”

Section: Tissue Parameterscontrasting

confidence: 84%

Carboplatin-induced Fanconi-like syndrome in rats: Amelioration by pentoxifylline

Khakhariya

Rathod

Gandhi

et al. 2014

Environmental Toxicology and Pharmacology

View full text Add to dashboard Cite

Section: Tissue Parameterscontrasting

confidence: 84%

Carboplatin-induced Fanconi-like syndrome in rats: Amelioration by pentoxifylline

Khakhariya

Rathod

Gandhi

et al. 2014

Environmental Toxicology and Pharmacology

View full text Add to dashboard Cite

“…In a previous study, RSV was reported to exert its nephroprotective effect through nitric oxide (NO) release thus lowering serum creatinine level and attenuating renal dysfunction (Chander & Chopra, 2006;Xia et al, 2014). NAC was reported to decrease renal injury secondary to hepatic injury, attributed to its oxygen free radical scavenging activity as well as its vasodilator effect (Seifi et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

Protective effect of ursodeoxycholic acid, resveratrol, andN-acetylcysteine on nonalcoholic fatty liver disease in rats

Ali

Messiha

Abdellatif

2015

Pharmaceutical Biology

View full text Add to dashboard Cite

(2016) Protective effect of ursodeoxycholic acid, resveratrol, and Nacetylcysteine on nonalcoholic fatty liver disease in rats, Pharmaceutical Biology, 54:7, 1198-1208, DOI: 10.3109/13880209.2015 -a), glucose, albumin, renal functions (urea, creatinine), lipid profile (total cholesterol; TC, triglycerides, high density lipoproteins, low density lipoproteins; LDL-C, very low density lipoproteins, leptin), and oxidative stress markers (hepatic malondialdehyde; MDA, glutathione; GSH, glutathione-S-transferase; GST) were measured using automatic analyzer, colorimetric kits, and ELISA kits, supported by a liver histopathological study.Results: RSV and NAC administration significantly improved liver index (RSV only), alanine transaminase (52, 52%), TNF-a (70, 70%), glucose (69, 80%), albumin (122, 114%), MDA (55, 63%), GSH (160, 152%), GST (84, 84%), TC (86, 86%), LDL-C (83, 81%), and leptin (59, 70%) levels compared with steatosis control values. A combination of RSV or NAC with UDCA seems to ameliorate their effects. Discussion and conclusion: RSV and NAC are effective on NAFLD through antioxidant, antiinflammatory, and lipid-lowering potentials, where as RSV seems better than UDCA or NAC.

show abstract

“…The study showed that PTX had no useful effects, instead NAC was useful in preventing tissue damage in hepatic ischemia/reperfusion injury; additionally, pretreatment with PTX and NAC combined before liver I/R was useful to ameliorate renal oxidative damage by preservation of cellular GSH concentration and reduction in MDA levels. [17,60] PTX was also used in a combined therapy with Alpha-tocopherol to find synergies with Vitamin E, a powerful antioxidant agent and an inhibitor of lipid peroxidation and the apoptosis processes [8], an effect also attributed to coenzyme Q10, which also had positive effects in combination with PTX [61]. In a 2010 paper [37], Camara-Lemarroy and his group utilized PTX associated with Thalidomide seeking to boost the inhibition of TNF-α and the lipidic peroxidation in I/R models of intestinal, hepatic and pulmonary damage.…”

Section: Ptx Combined With Other Drugs For the Treatment Of I/r Damagementioning

confidence: 98%

Pentoxifylline in Liver Ischemia and Reperfusion

Genovés

García

Cejalvo‐Lapeña

et al. 2013

Journal of Investigative Surgery

View full text Add to dashboard Cite

Pentoxifylline is a methylxanthine compound which was first filed in 1973 and registered in 1974 in the United States by Sanofi-Aventis Deustchland Gmbh for the treatment of intermittent claudication for chronic occlusive arterial disease. This methylxanthine was later discovered to be a phosphodiesterase inhibitor. Furthermore, its hemorheological properties and its function as an inhibitor of inflammatory cytokines, like TNF-α, allowed researchers to study its effects in organ ischemia and reperfusion and transplantation. Although this drug has demonstrated beneficial effects, the mechanisms by which Pentoxifylline exerts a protective effect are not fully understood. This paper focuses on reviewing the literature to define the effect of Pentoxifylline when used in liver ischemia and reperfusion injury. Our research shows different animal models in which Pentoxifylline has been used as well as different doses and time of administration, as the ideal dose and timing have not yet been ascertained in liver ischemia and reperfusion. In conclusion, Pentoxifylline has shown positive effects in liver ischemia and reperfusion injury, and the main mechanism seems to be associated with the inhibition of TNF-α.

show abstract

Pretreatment with Pentoxifylline andN-Acetylcysteine in Liver Ischemia Reperfusion-Induced Renal Injury

Cited by 31 publications

References 34 publications

Carboplatin-induced Fanconi-like syndrome in rats: Amelioration by pentoxifylline

Carboplatin-induced Fanconi-like syndrome in rats: Amelioration by pentoxifylline

Protective effect of ursodeoxycholic acid, resveratrol, andN-acetylcysteine on nonalcoholic fatty liver disease in rats

Pentoxifylline in Liver Ischemia and Reperfusion

Contact Info

Product

Resources

About